PART I Overview We are a biopharmaceutical company that has developed ONS-5010/LYTENAVA TM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD. In June 2025, we launched directly into the initial markets of Germany and the UK. Additionally, our Bi...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-19 | 2025-09-30 | 0001104659-25-123264 | EDGAR | 98K words |
| 2024-12-27 | 2024-09-30 | 0001558370-24-016491 | EDGAR | — |
| 2023-12-22 | 2023-09-30 | 0001558370-23-020000 | EDGAR | — |
| 2022-12-29 | 2022-09-30 | 0001558370-22-019036 | EDGAR | — |
| 2021-12-23 | 2021-09-30 | 0001558370-21-017007 | EDGAR | — |
| 2020-12-23 | 2020-09-30 | 0001558370-20-014540 | EDGAR | — |
| 2019-12-19 | 2019-09-30 | 0001104659-19-074095 | EDGAR | — |
| 2018-12-18 | 2018-09-30 | 0001144204-18-065142 | EDGAR | — |
| 2017-12-29 | 2017-09-30 | 0001571049-17-008779 | EDGAR | — |
| 2016-12-29 | 2016-09-30 | 0001571049-16-020882 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001104659-26-016554 | EDGAR | 23K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011588 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001558370-25-007873 | EDGAR | — |
| 2025-02-14 | 2024-12-31 | 0001558370-25-001022 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012234 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008318 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0001558370-24-001172 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014866 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009942 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0001558370-23-001286 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013086 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001558370-22-008780 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001104659-26-034601 | EDGAR | 21K words |
| 2026-03-16 | 0001104659-26-028103 | EDGAR | — |
| 2026-03-11 | 0001104659-26-026465 | EDGAR | — |
| 2026-03-10 | 0001104659-26-025893 | EDGAR | — |
| 2026-03-05 | 0001104659-26-024189 | EDGAR | — |
| 2026-02-18 | 0001104659-26-017118 | EDGAR | — |
| 2026-02-17 | 0001104659-26-015887 | EDGAR | — |
| 2026-02-11 | 0001104659-26-013470 | EDGAR | — |
| 2026-01-02 | 0001104659-26-000066 | EDGAR | — |
| 2025-12-19 | 0001104659-25-122786 | EDGAR | — |
256 total filings indexed. 224 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001649989 |
| Ticker | OTLK |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.outlooktherapeutics.com |
| Listed | 2016-05-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report